logo-loader
HealthPharma & Biotech
Circassia Pharmaceuticals PLC

Circassia Pharma gets UK approval for asthma challenger

The marketing application includes all three strengths of fluticasone propionate

Heart-cells_56545ad4c0001.jpg
Circassia acquired fluticasone through its acquisition of Prosonix in June

Circassia Pharmaceuticals (LON:CIR) shares edged higher as its new asthma inhaler was recommended for a UK licence opening the way for marketing across Europe.

The UK regulator (MHRA) acted as a referee for the product, which will now be submitted under the Mutual Recognition Procedure for approval in other EU member states.

The marketing application includes all three strengths of fluticasone propionate where the current standard, GlaxoSmithKline’s Flixotide, is available and will be eligible for direct substitution of Glaxo’s product in countries that give approval.

Circassia added the positive regulatory outcome also represented an important validation of its particle-engineering platform in an area where products, and respiratory medicines especially, are difficult to manufacture.

It was the first time a marketing application for a respiratory product of different strengths had been approved using in vitro data only and without a clinical trial, the pharma company added.

Steve Harris, Circassia's chief executive, said: "Achieving this positive outcome is a major milestone for Circassia, marking the favourable conclusion of the company's first ever Marketing Authorisation Application for a product using its particle-engineering technology.

Circassia acquired the technology through its acquisition of Prosonix in June and it has been developed in collaboration with Dutch group Mylan.

Shares rose  6% to 280p.

Quick facts: Circassia Pharmaceuticals PLC

Price: £0.18

Market: LSE
Market Cap: £66.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

2 days, 13 hours ago

Holding(s) in Company

3 days, 11 hours ago

Holding(s) in Company

4 days, 11 hours ago

Holding(s) in Company

4 days, 11 hours ago

Holding(s) in Company

5 days, 15 hours ago

Holding(s) in Company

5 days, 16 hours ago

Holding(s) in Company

6 days, 11 hours ago

Block listing Interim Review

1 week, 2 days ago